GW Pharmaceuticals Plc GWPHV

$GWPH: Why Investors Should be Bullish About GWPH

[Isodog2018]

"We believe GW Pharmaceuticals is a possible buying opportunity for two reasons. The first reason is that GW Pharmaceuticals is poised to start selling in Europe in 2020 as the European Commission approved GW Pharmaceuticals Epidiolex as a treatment for seizures in two rare and severe forms of epilepsy. This should add to their revenue as they push towards profitability. Once the company can achieve profitability in a sector where investors’ patience is growing thin, it should make the company stand out in the crowd and solidify their business model. This could in itself restore investor confidence despite their growth concerns."

https://stocknews.com/news/gwph-why-investors-should-be-bullish-gw-pharmaceuticals-gwph/

Europe 2020

[Isodog2018]

  "Second, the company is still releasing data like they did last week proving that Epidiolex has further uses and they will be able to hopefully expand their product line. The stock currently trades at 52-week lows which in our opinion presents a unique buying opportunity to own a company that has very little competition in a high growth niche market. Therefore, keep it on your

[Livestrea3m]

This post has been removed in accordance with Community Policy

[indaknownewfie]

Could they be partnering with another company  like Kalytera therapeutics v.kly who received an exclusive European patent this past Friday through Mor for CBD used to Prevent and Treat acute and chronic GvHd, Graft versus Host Disease. They received their US patent for same of Feb.. 5th, 2020

[norandos]

This post has been removed in accordance with Community Policy